Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02580045 · ClinicalTrials.gov registry record

Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer

A clinical trial, sponsored by Duke University.

Terminated
Registry status
3
Enrollment target

NCT02580045 is a clinical trial that was terminated before completion, run by Duke University. The registered enrollment target is 3 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02580045 was terminated before completion, sponsored by Duke University.

TERMINATED
Registry status
3 participants
Enrollment target

Study Summary

This clinical trial is being done to learn more about how different types of cancer treatments affect cancer cells when they spread to the brain. Many cancer treatments are not able to make their way into the brain or into spinal fluid of the central nervous system. This is because they cannot cross what is called the "blood-brain barrier" or "BBB". The BBB is like a protective shield that only allows certain materials pass through to reach the brain but not others. This study is being initiated to help researchers learn more about what types of cancer treatments make it through the BBB to attack cancer cells within the brain, and what treatments do not make it through the BBB. Learning more about this may help future researchers develop more effective cancer drugs that better fight cancer cells that have spread to the brain.

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2016-04-01
Est. Completion 2018-02-22

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT02580045

The ClinicalTrials.gov registry entry for NCT02580045 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02580045 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02580045 about?

NCT02580045 is a clinical study titled "Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer". This clinical trial is being done to learn more about how different types of cancer treatments affect cancer cells when they spread to the brain. Many cancer treatments are not able to make their way into the brain or into spinal fluid of the central nervous system. This is because they cannot cross...

What is the current status of trial NCT02580045?

This trial is currently terminated. The enrollment target is 3 participants. The study started on 2016-04-01. Estimated completion is 2018-02-22.

Who is sponsoring clinical trial NCT02580045?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.